Literature DB >> 25576145

[Abscopal effect in the treatment of malignant melanoma].

C Thallinger1, G Prager, H Ringl, C Zielinski.   

Abstract

BACKGROUND: The clearance of non-irradiated tumors after localized radiation therapy is known as the abscopal effect. CASE REPORT: In the present case report we initiated a combined therapeutic approach based on sequential administration of ipilimumab plus temozolomide in combination with radiotherapy. The treatment regime was well tolerated and resulted in unusually long disease stabilization and in a complete response of brain and kidney metastases. Thus, it is speculated that the clinical response was the result of an abscopal effect.
CONCLUSION: The present case report highlights the possible clinical benefit of the abscopal effect in the treatment of malignant melanoma.

Entities:  

Mesh:

Year:  2015        PMID: 25576145     DOI: 10.1007/s00105-014-3567-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  13 in total

Review 1.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

2.  Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Authors:  Jeffrey S Weber; Asim Amin; David Minor; Jonathan Siegel; David Berman; Steven J O'Day
Journal:  Melanoma Res       Date:  2011-12       Impact factor: 3.599

3.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Authors:  Anna Maria Di Giacomo; Paolo A Ascierto; Lorenzo Pilla; Mario Santinami; Pier Francesco Ferrucci; Diana Giannarelli; Antonella Marasco; Licia Rivoltini; Ester Simeone; Stefania Vl Nicoletti; Ester Fonsatti; Diego Annesi; Paola Queirolo; Alessandro Testori; Ruggero Ridolfi; Giorgio Parmiani; Michele Maio
Journal:  Lancet Oncol       Date:  2012-08-13       Impact factor: 41.316

4.  Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Authors:  M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

5.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

6.  Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.

Authors:  Satoko Matsumura; Baomei Wang; Noriko Kawashima; Steve Braunstein; Michelle Badura; Thomas O Cameron; James S Babb; Robert J Schneider; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-09       Impact factor: 7.038

Review 8.  Melanoma brain metastasis: overview of current management and emerging targeted therapies.

Authors:  Ekokobe Fonkem; Erik J Uhlmann; Scott R Floyd; Anand Mahadevan; Ekkehard Kasper; Omar Eton; Eric T Wong
Journal:  Expert Rev Neurother       Date:  2012-10       Impact factor: 4.618

9.  Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment.

Authors:  Sandra Demaria; Karsten A Pilones; Silvia C Formenti; Michael L Dustin
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

10.  Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.

Authors:  B Sherrill; J Wang; S Kotapati; K Chin
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640

View more
  4 in total

Review 1.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

Review 2.  Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Authors:  Christiane Thallinger; Thorsten Füreder; Matthias Preusser; Gerwin Heller; Leonhard Müllauer; Christoph Höller; Helmut Prosch; Natalija Frank; Rafal Swierzewski; Walter Berger; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2017-11-02       Impact factor: 1.704

Review 3.  Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review.

Authors:  Xinqing Lin; Tingting Lu; Zhanhong Xie; Yinyin Qin; Ming Liu; Xiaohong Xie; Shiyue Li; Chengzhi Zhou
Journal:  Thorac Cancer       Date:  2019-03-30       Impact factor: 3.500

Review 4.  Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review.

Authors:  Junko Takahashi; Shinsuke Nagasawa
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.